ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
In 2022, 464 000 people died from human papillomavirus (HPV)-related cancer. Despite the availability of safe, highly effective HPV vaccinations, global coverage is just 20% for girls and 7% for boys. We summarized the evidence for target vaccination age and found that vaccinating at age 9-10 years, the youngest end of the World Health Organization's (WHO) recommended age range, has multiple advantages. Earlier vaccination increases the likelihood of vaccinating before HPV exposure, may reduce the impact of sex-associated stigma, and is logistically advantageous through enabling primary-school immunization and program resilience. Furthermore, we systematically reviewed published immunogenicity data on children aged 9-15 years and identified that vaccination at age 9 is immunologically robust. Globally, most countries target ages 11 years or older for HPV vaccination. Our findings indicate an urgent need to target earlier ages to help achieve the WHO's goal to vaccinate 90% of girls against HPV by age 15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.